BackEikon Therapeutics Common Stock Overview

Eikon Therapeutics Common Stock Total Liabilities

Track Eikon Therapeutics Common Stock's total liabilities ($300M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$300.15M

Peer average / median

Loading

Eikon Therapeutics Common Stock Total Liabilities History

Loading

Eikon Therapeutics Common Stock vs. peers: Total Liabilities Comparison

Loading

Eikon Therapeutics Common Stock Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Eikon Therapeutics Common Stock (EIKN) FAQ

The latest total liabilities for EIKN is $300M as of March 2026. Investors often review this figure alongside Eikon Therapeutics Common Stock's historical trend and sector peers before judging valuation or financial health.

A total liabilities figure of $300M for EIKN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EIKN's total liabilities ($300M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Eikon Therapeutics Common Stock's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.